PDCD1 and neoplasm: Pembrolizumab is a highly selective humanized monoclonal antibody that binds to the PD-1 receptor and directly blocks the interaction between PD-1 and its ligand, thereby enhancing the function of tumor-directed T cells and mediating tumor destruction (37).